A nurse is assisting with care of a client who has a prescription for 3,000 mL of intravenous fluids over the next 24 hr. The nurse should set the IV pump to deliver how many mL/hr? (Round to the nearest whole number)

A. The herbal product must contain only one active ingredient:

This statement is not a legal requirement contained in DSHEA. Many dietary supplements contain multiple active ingredients, such as vitamins, minerals, herbs, amino acids, and other substances. DSHEA does not mandate that dietary supplements contain only one active ingredient.

B. Effectiveness must be demonstrated by the manufacturer:

DSHEA does not require manufacturers to demonstrate the effectiveness of dietary supplements before marketing. Unlike pharmaceutical drugs, which must undergo premarket approval by the Food and Drug Administration (FDA) to demonstrate safety and efficacy, dietary supplements do not need to prove effectiveness to be marketed. Instead, manufacturers are responsible for ensuring the safety of their products and making truthful claims on product labels.

C. Dietary supplements must state that the product is not intended to diagnose, treat, cure, or prevent any disease:

This statement accurately reflects a legal requirement contained in DSHEA. Under DSHEA, dietary supplement labels must include a disclaimer stating that the product is not intended to diagnose, treat, cure, or prevent any disease. This disclaimer helps to clarify that dietary supplements are intended to support general health and well-being rather than to treat specific diseases or medical conditions.

D. Dietary supplements must be tested for safety prior to marketing:

While DSHEA requires manufacturers to ensure the safety of their dietary supplements, it does not mandate standardized premarket testing for safety by regulatory authorities. Instead, manufacturers are responsible for conducting safety assessments and ensuring that their products are safe for consumers. The FDA may take action against manufacturers if a product is found to be unsafe or if it violates regulatory requirements, but premarket testing is not a specific legal requirement under DSHEA.

A. Discoloration of body fluids:

Vancomycin can cause discoloration of body fluids, particularly urine, resulting in a brownish discoloration. However, this is not caused by histamine release.

B. Ototoxicity:

Ototoxicity refers to damage to the inner ear structures leading to hearing loss or balance problems. While vancomycin can cause ototoxicity, it is not specifically associated with histamine release.

C. Red-man syndrome

Red-man syndrome, also known as red-neck syndrome or red-person syndrome, is a hypersensitivity reaction characterized by flushing of the skin, particularly the upper body and face, resembling a "red man." This reaction is typically associated with the rapid infusion of vancomycin and is caused by the release of histamine from mast cells and basophils. It is not an allergic reaction but rather a non-immunologic response to vancomycin.

D. Nephrotoxicity:

Nephrotoxicity refers to kidney damage caused by certain medications or toxins. While vancomycin can cause nephrotoxicity, it is not specifically associated with histamine release.